Kornimate/medical-research-clean huggingface dataset:
glucocorticoid therapy in coronavirus disease covid-19 patients

Conditions: Corona Virus Infection

Summary: treatment with glucocorticoids in covid patients. low-intervention, phase iv, open-label, randomised, low-intervention clinical trial comparing 2 active treatments.

the use of high-dose bolus glucocorticoids in the treatment of patients with covid-19 infection will increase the anti-inflammatory effect without increasing side effects. this will allow a better patient outcome, reducing the number of deaths and the need for intubation or admission to the intensive care unit.

Eligibility criteria:
inclusion criteria: 1. over 18 years of age 2. inpatient 3. diagnosis of sars-cov-2 infection confirmed by reverse transcriptase polymerase chain reaction (rt-pcr) or antigen 4. they present evidence in computerized axial tomography (ct) of pulmonary involvement attributed to the infection by covid. patients in whom ct scans are not performed must have suspected pulmonary involvement by clinical examination with simple compatible or suggestive radiology. 5. requires supplementary oxygen due to basal saturation ≤ 93% (with ambient o2, 21%) exclusion criteria: 1. the patient's situation is so serious that the doctor in charge thinks he could die within 24 hours. 2. at the time of randomisation, patients require one of the following 4 ventilatory supports: 1. high-flow oxygen devices. 2. non-invasive mechanical ventilation. 3. invasive mechanical ventilation. 4. extracorporeal membrane oxygenation (ecmo). 3. the patient is or has been treated in the 2 weeks prior to randomisation with glucocorticoids or inflammation modifying drugs, both conventional (thiopurines, cyclophosphamide, cyclosporine, tacrolimus), leflunomide, methotrexate, mycophenolate mofetil/mycophenolic acid, sulfasalazine, hydroxychloroquine or chloroquine) as synthetics or biologics directed against therapeutic targets (abatacept, belimumab, cd-20, il1, il6, il12. 23, il-23, il.17, tnf, integrin α4β7 or janus kinase inhibitors jak). patients who are only on maintenance treatment with doses of steroids less than or equal to 7.5 mg of prednisone or equivalent per day will not be excluded. 4. the patient is pregnant or breastfeeding. 5. the patient has a chronic renal disease is stage 4 or 5 (ccr \<30 ml/min). 6. moderate to severe dementia at the investigator's discretion. 7. hypersensitivity to any of the active ingredients or to any of the excipients included in its formulation. 8. untreated systemic infections not caused by covid-19. 9. active stomach or duodenal ulcer. 10. recent vaccination with live vaccines. 11. other infection or disease that explains the lung disorder. 12. inability of the patient to understand the study or to sign the informed consent unless consent is delegated to a legal representative. 13. active participation in another clinical study in the last 15 days.
parafricta bootees vs uk standard care to prevent heel pressure ulcers

Conditions: Pressure Ulcer; Pressure Injury; Heel Ulcer

Summary: this randomised study will assess whether parafricta bootees, when used in addition to normal standard care, can reduce the incidence of heel pus in patients at very high risk of skin breakdown. the participant group will be hospital inpatients at high risk of pus (waterlow score of 20 or more) who are bedbound and do not have existing heel pus. the participants will be randomised to an intervention arm using parafricta plus standard care, or a control arm of standard care only. the primary outcome is incidence of heel pus at day 3. secondary outcomes are incidence of pus at day 14, length of stay, severity of pus, patient acceptability of device, cost-effectiveness.


Eligibility criteria:
inclusion criteria: the eligibility criteria for this study at the time of recruitment were: * adult of age 18 years or over * admitted to secondary care in an in-patient hospital (with no specified interval from admission to hospital to study recruitment) * bedbound or unable to walk independently and requiring assistance to transfer to a chair * 'very high' risk group for pressure ulceration (defined by a waterlow score of 20 or more) * no existing heel pressure ulcers of epuap/npuap/pppia category 1 or above or any other type of wound on the feet. * patient was not being treated with pressure offloading boots. * patient was not being treated with a heel cast. exclusion criteria: • patients with a single or double lower limb amputation were not eligible to participate in the study.

Keywords: parafricta pressure ulcer
acceptability and feasibility of micronutrient powders versus iron syrup for anemia prevention in young children

Conditions: Anemia

Summary: this study seeks to assess the acceptability, compliance, and preference for iron supplementation; micronutrient powders (mnp) versus iron syrup. additionally, this study seeks to assess front line health worker perceptions and experiences regarding ease of implementation of each strategy and delivery strategy preference.

the specific aims of this study are to assess the acceptability of, compliance, and preference for two delivery vehicles for pediatric prophylaxis iron supplementation (micronutrient powders (mnp) that contain iron versus iron syrup) among rural households in bihar india delivered through home visits by front line health workers. additionally, this study seeks to assess front line health worker perceptions and experiences regarding ease of implementation of each strategy and delivery strategy preference.

Eligibility criteria:
inclusion criteria: * singleton children or one child per home exclusion criteria: * currently taking iron supplements * mid upper arm circumference (muac) or less than 11.5 cm * suspected severe anemia * known case of haemoglobinopathy * history of repeated blood transfusion * current pneumonia * current fever * acute diarrhea
compare fallopian tube cells collected by cytuity with removed ovarian/tubal tissue to determine presence of malignancy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Ovarian Neoplasms; Ovary Cancer; Fallopian Tube Neoplasms; Fallopian Tube Adenocarcinoma; High Grade Serous Carcinoma; Peritoneal Carcinoma; Peritoneal Neoplasms; Adnexal Mass; Ovarian Diseases

Summary: prospective, multi-center, non-randomized study to assess the ability of the cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.


Eligibility criteria:
inclusion criteria: 1. subject is medically cleared for surgery 2. subject is scheduled to undergo salpingo-oophorectomy or salpingectomy for a pelvic mass suspicious for malignancy 3. subject must be 18 years of age 4. subject must be able to provide informed consent exclusion criteria: 1. contraindication to hysteroscopy 2. acute pelvic inflammatory disease 3. active or recent lower pelvic infection 4. pregnancy 5. delivery or termination of a pregnancy in the past 6 weeks 6. known tubal obstruction 7. tubal ligation 8. invasive carcinoma of the cervix or endometrium 9. intolerance of anesthesia

Keywords: salpingo-oophorectomy salpingectomy ovarian cancer fallopian tube cancer high grade serous carcinoma hysteroscopic biopsy fallopian tube cell collection peritoneal cancer
glaucoma evaluation with the p200te

Conditions: Glaucoma

Summary: images captured on the p200te device on glaucoma patients


Eligibility criteria:
inclusion criteria * subjects were 22 years of age or older on the date of informed consent; * subjects were able to understand the written informed consent and willing to participate as evidenced by signing the informed consent; * bcva 20/40 or better in the study eye; * history of visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings: on pattern deviation (pd), there existed a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; or glaucoma hemi-field test "outside normal limits;" -glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage; and optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue. exclusion criteria * subjects unable to tolerate ophthalmic imaging; * subjects with ocular media not sufficiently clear to obtain acceptable oct images in the study eye; * subject has a condition or is in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study; * no reliable visual field test result within the past year of the study visit, defined as fixation losses \> 33% or false positives \>33%, or false negatives \>33% in the study eye; * presence of any ocular pathology except glaucoma in the study eye.
extracorporeal shock wave therapy on wrist and hand functions in spastic chronic stroke patients

Conditions: Stroke; Spasticity; Shock Wave

Summary: 40 chronic stroke patients with upper limb spasticity will randomly divided into two groups. first group will receive 3 sessions of radial extracorporeal shock wave therapy (reswt) with one week apart without cessation of current physical therapy, while the second group will continue to receive conventional rehabilitative program. assessment will be done at baseline, 2 weeks after reswt and 3 months after reswt using modified ashworth scale, fugl meyer assessment for hand function and wrist control, motricity index for pinch grip and hmax/ mmax amplitude ratio of flexor carpi radialis muscle.


Eligibility criteria:
inclusion criteria: * patients with chronic stroke with disease duration more than one year will be included in the study with stable modified ashworth scale for upper limb spasticity ranged from 1+ to 4. exclusion criteria: * patients more than 65 years,patients with double stroke and patients with fixed contractures of wrist \& hand ,patients received anti-spastic measures (botulinum toxins, nerve block) within 6 months,also patients with contraindication to extra-corporeal shock wave therapy i.e. malignancy at treatment area, coagulopathies, active infection (viral or tb), o bleeding wounds, and patients with pacemakers will be excluded

Keywords: shock wave
evaluation of a theory-driven manualized approach to improving new learning and memory in ms

Conditions: Multiple Sclerosis

Summary: the purpose of this research study is to investigate the effectiveness of a memory enhancement technique in persons with multiple sclerosis.

the purpose of this research study is to investigate the effectiveness of a memory enhancement technique in persons with multiple sclerosis (ms). the study is designed to research how well this technique can help people with ms improve their memory and their ability to function better in everyday life.

Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis * ability to read and speak english fluently * difficulties with learning and memory skills exclusion criteria: * prior diagnosis of stroke or other neurological injury/disease * flare up of symptoms within a month of study participation * history of significant psychiatric illness (e.g., bipolar disorder, schizophrenia, psychosis) or current diagnosis of major depressive disorder, schizophrenia, bipolar disorder i or ii * current significant alcohol or substance abuse * taking exclusionary medication (study team will review medications) for optional mri: * pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments. * dental implants * left-handed

Keywords: multiple sclerosis ms relapsing-remitting ms progressive ms rrms ppms spms primary progressive secondary progressive
does the natural medicinal plant st john's wort affect the glucose tolerance in healthy individuals

Conditions: Type 2 Diabetes

Summary: the goal of the study is to examine if healthy individuals that ingest st john's wort will have a significantly difference in glucose tolerance.


Eligibility criteria:
inclusion criteria: * 18-40 years * males * fasting plasma-glucose \< 7.0 mmol/l * glycosylated haemoglobin a1c within reference or clinically insignificant deviation hereof * body mass index \< 30 kg/m\^2 exclusion criteria: * hypersensitivity to st john's wort * chronical or daily alcohol abuse * known liver disease * ingestion of drugs requiring prescription, except locally acting drugs

Keywords: glucose tolerance
repeat-dose of forodesine hydrochloride (bcx-1777) infusion in patients with advanced t-cell leukemia

Conditions: Leukemia, T-Cell

Summary: bcx-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. the phase ii trial is designed to study the effectiveness of bcx-1777 in treating patients who have recurrent or refractory advanced t-cell leukemia. patients will receive an infusion of bcx-1777 on days 1-5. treatment may be repeated every week for up to six courses. patients are not required to be hospitalized for the administration of bcx-1777. some patients may continue to receive an infusion of bcx-1777 twice a week for 6 weeks.

bcx-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. the phase ii trial is designed to study the effectiveness of bcx-1777 in treating patients who have recurrent or refractory advanced t-cell leukemia.

Eligibility criteria:
inclusion criteria: * documented t-cell leukemia (precursor t-lymphoblastic leukemia/lymphomia or t-pll) * failure to have responded to one or more standard regimens for their disease. * performance status of \<=2 by eastern cooperative oncology group (ecog) criteria * all ages are eligible * life expectancy of at least 3 months * adequate liver function (aspartate transaminase \[ast\] and/or alanine transaminase \[alt\] not \>3 times upper limits or normal \[uln\]) * adequate kidney function (calculated creatinine clearance \>50 ml/min) * negative urine pregnancy test within 2 to 7 days prior to the start of study treamtment in females of childbearing potential * females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study * signed informed consent/assent form (icf) prior to start of any study specific procedures exclusion criteria: * patients with known hiv infection or human t-cell leukemia virus type (htlv-1) * patients with known hepatitis b and/or hepatitis c active infection * patients with active cmv infection * tumor-related central nervous system (cns) leukemia requiring active treatment * active serious infection not controlled by oral or iv antibiotics * treatment with any investigational anti-leukemic agent or chemotherapy agent within 7 days prior to study entry, unless full recovery from side effects has occurred. * rapidly progressive disease with compromised organ function judged to be life-threatening by the investigator * concurrent treatment with other anticancer agents (corticosteroid use will not be excluded, but patient must remain on the stable dose) * cutaneous t-cell lymphoma (ctcl) diagnosis (including sezary syndrome) * pregnant and/or lactating women

Keywords: leukemia, lymphocytic, t-cell entry term lymphocytic leukemia, t-cell t-cell leukemia t-lymphocytic leukemia leukemia, lymphocytic, t cell t lymphocytic leukemia bcx-1777 forodesine hydrochloride biocryst
investigating the effect of evidence-based treatment for post-traumatic stress disorder among youth

Conditions: Trauma; Mental Health Disorder; PTSD; Implementation

Summary: trauma-focused cognitive-behavioral therapy (tf-cbt) is an evidence-based practice (ebp) for the treatment of posttraumatic stress disorder (ptsd) and posttraumatic stress symptoms (ptss) among children and adolescents. in the current study, data were collected from youth receiving tf-cbt in specialized child and adolescent mental health services (camhs) and their caregivers in 2018-2021.

implementation of tf-cbt is a state-wide initiative, funded by the norwegian ministry of health and care services, and is without costs for the clinics and patients. the norwegian center for violence and traumatic stress studies (nkvts) is responsible for the project. tf-cbt trainers at nkvts train therapists at the participating camhs in tf-cbt. data are collected to monitor the training and patient outcomes. data are collected anonymously to support and ensure high-quality treatment and also provide the opportunity to investigate the effect of the implementation of tf-cbt in norwegian camhs. in the period 2018-2021, additional data were collected as part of a larger study where the aim was to investigate the effect of the implementation leadership support on implementation outcomes (clinicaltrials.gov identifier: nct03042832). data were collected through online questionnaires before, during, and after tf-cbt was provided based on usual care. routine procedures for trauma exposure screening and related posttraumatic stress symptoms were implemented. those who scored above a predefined clinical cut-off were enrolled into tf-cbt based on the child and her or his caregiver's consent. the aim of the study is to investigate the patient outcomes and therapeutic processes in tf-cbt.

Eligibility criteria:
inclusion criteria: * referred to norwegian camhs * screened for trauma exposure and ptss exclusion criteria: * below the age of 6 and above the age of 18

Keywords: tf-cbt trauma treatment ptsd and complex ptsd mental health organization
impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients

Conditions: Pneumonia, Bacterial; Cancer; Pneumococcal Infections

Summary: according to the world health organization (who), immunization; is defined as making a person immune or resistant to an infectious disease by applying a vaccine (1). the primary indicator of an effective immunization is that adequate vaccination rates have been achieved. the risk of cancer and chronic diseases increases with advancing age, which increases the importance of immunization in adults. cancer patients, one of the patient groups for whom adult immunization is a priority and crucial, are subjected to immunosuppressive medications, making them vulnerable to infections. in cancer patients, infections are severe, antimicrobial treatments are sometimes insufficient, leading to morbidity and mortality. one of these infections is pneumococcal disease caused by streptococcus pneumonia, with high morbidity and mortality in cancer patients. invasive pneumococcal disease is seen 23-48 times more frequently in cancer patients compared to healthy individuals. in many countries worldwide, the 13-valent pneumococcal conjugate vaccine and the 23-valent polysaccharide pneumococcal vaccine, both developed to prevent pneumonia caused by streptococcus pneumonia, are successfully used in childhood vaccination programs within the framework of who's immunization policies. however, in turkey, like in the rest of the world, the required adult immunization rates have not been achieved yet. immunization rates among cancer patients, one of the patient groups for whom adult vaccination is required, remain below the targeted levels. pharmacists, one of the health professionals, have significant contributions to increasing vaccination rates in adults. according to studies, pharmacists can help raise immunization rates by providing education and information. in turkey, no study has been conducted to assess the impact of vaccination education on cancer patients' attitudes and actions about the pneumococcal vaccine. this study aimed to determine the impact of pharmacist-led pneumonia and pneumococcal vaccine education on cancer patients' vaccination attitudes, knowledge, and vaccination rates.


Eligibility criteria:
inclusion criteria:the study will involve patients who have all of the following features simultaneously. * patients who visit medical oncology outpatient clinics, * patients who are over 18 years old, * patients who have been diagnosed with cancer for less than two years, * patients who are in remission stage (as determined by a medical oncologist), * patients who have never had the pneumococcal vaccine. exclusion criteria: * patients who could not communicate in turkish, * patients who were illiterate, * patients who had visual/auditory/cognitive impairments, * patients who had previously received a pneumococcal vaccine recommendation, * patients who did not know their pneumococcal immunization status * patients who want to leave the study
a deep learning framework for pediatric tle detection using 18f-fdg-pet imaging

Conditions: Epilepsy, Temporal Lobe

Summary: this study aims to use radiomics analysis and deep learning approaches for seizure focus detection in pediatric patients with temporal lobe epilepsy (tle). ten positron emission tomograph (pet) radiomics features related to pediatric temporal bole epilepsy are extracted and modelled, and the siamese network is trained to automatically locate epileptogenic zones for assistance of diagnosis.

purpose:the key to successful epilepsy control involves locating epileptogenic focus before treatment. 18f-fdg pet has been considered as a powerful neuroimaging technology used by physicians to assess patients for epilepsy. however, imaging quality, viewing angles, and experiences may easily degrade the consistency in epilepsy diagnosis. in this work, the investigators develop a framework that combines radiomics analysis and deep learning techniques to a computer-assisted diagnosis (cad) method to detect epileptic foci of pediatric patients with temporal lobe epilepsy (tle) using pet images. methods:ten pet radiomics features related to pediatric temporal bole epilepsy are first extracted and modelled. then a neural network called siamese network is trained to quanti-fy the asymmetricity and automatically locate epileptic focus for diagnosis.the performance of the proposed framework was tested and compared with both the state-of-art clinician software tool and human physicians with different levels of experiences to validate the accuracy and consistency.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of temporal lobe epilepsy. 2. age range from six to eighteen years old. 3. underwent pet, eeg, computed tomography (ct) and mri. exclusion criteria: 1. image quality is unsatisfactory (e.g. severe image artifacts due to head movement). 2. 18f-fdg peg examination is negative. 3. clinical data is incomplete. 4. eeg or mri report is missing.

Keywords: deep learning temporal lobe epilepsy positron-emission tomography